Global Medicare · Publications & Evidence
The evidence behind the scientific questions.
Explore clinical studies, randomized trials, observational research and biological background relevant to Global Medicare’s ovarian and endometrial research programs.
Published findings are heterogeneous and should be interpreted according to study design, population and clinical context.
Reading the evidence
Not every publication answers the same question.
Study design matters. A randomized clinical trial, a prospective cohort, a pilot study and a biological review provide different types and levels of information.
Designed for controlled comparison between groups.
Observes outcomes prospectively in a defined population.
Provides preliminary clinical information in smaller samples.
Synthesizes previously published scientific literature.
Preliminary scientific communication rather than a full article.
Ovarian Clinical Evidence
Intraovarian PRP: promising signals, heterogeneous results.
Published studies have evaluated intraovarian PRP in women with poor ovarian response, diminished ovarian reserve and primary ovarian insufficiency.
Results differ between studies, and improvements in intermediate parameters do not necessarily translate into improved blastocyst quality, pregnancy or live birth.
Intraovarian platelet-rich plasma injection and IVF outcomes in patients with poor ovarian response
Double-blind randomized controlled trial. The study reported an increase in retrieved oocytes, without improvement in the quality of resulting blastocysts.
First data on IVF and blastocyst formation after intraovarian injection of autologous platelet-rich plasma
Early clinical data describing ovarian and IVF-related parameters following intraovarian autologous PRP.
Effects of intraovarian autologous platelet-rich plasma on ovarian reserve and IVF outcomes in primary ovarian insufficiency
Clinical study reporting ovarian-reserve and IVF-related outcomes after intraovarian PRP in women with primary ovarian insufficiency.
Reactivating ovarian function through autologous platelet-rich plasma intraovarian infusion
Pilot data involving premature ovarian insufficiency, perimenopausal, menopausal and poor-responder populations.
Preliminary report of intraovarian PRP in patients with extremely poor functional ovarian reserve
Prospective cohort that did not demonstrate clinically relevant improvement in ovarian function during the observation period.
Endometrial Clinical Evidence
PRP has been studied directly in thin endometrium and implantation-related settings.
Published research includes randomized trials, pilot studies and clinical cohorts examining endometrial expansion and reproductive outcomes after intrauterine PRP.
Effects of autologous platelet-rich plasma on endometrial expansion in frozen-thawed embryo transfer
Double-blind randomized controlled trial evaluating intrauterine PRP in patients with inadequate endometrial growth.
Can autologous PRP expand endometrial thickness and improve pregnancy rate during frozen embryo transfer?
Randomized clinical trial evaluating endometrial thickness and pregnancy outcomes in frozen-thawed embryo-transfer cycles.
Autologous PRP infusion improves clinical pregnancy rate in FET cycles for women with thin endometrium
Clinical study examining intrauterine PRP in women with thin endometrium undergoing frozen embryo transfer.
Autologous PRP treatment on refractory thin endometrium during frozen embryo-transfer cycles
Pilot study evaluating PRP treatment in refractory thin endometrium.
Intrauterine PRP and embryo implantation in women with repeated implantation failure
Single-arm self-controlled study examining endometrial thickness and implantation in recurrent implantation failure.
Biological Background
Platelets are more than components of haemostasis.
Activated platelets release growth factors, cytokines and other naturally occurring biological components involved in tissue signalling and repair.
This biological background helps explain why autologous platelet-rich preparations have been investigated across several medical disciplines.
Platelet-derived signalling includes PDGF, TGF-β, VEGF, EGF and other biological factors.
Platelet-derived factors participate in vascular and tissue-repair signalling.
Published biological research describes roles in extracellular-matrix and cellular responses.
Platelets also release extracellular vesicles that participate in intercellular communication.
Mechanistic Evidence
Extracellular-vesicle biology is scientific background — not proof of IAS efficacy.
Extracellular vesicles are naturally occurring membrane-bound particles involved in intercellular communication and the transport of biologically active molecules.
Research on platelet-derived extracellular vesicles provides mechanistic background relevant to regenerative biology.
This evidence must not be used to describe IAS as purified exosome therapy or to claim proven clinical superiority.
Advances in platelet-rich plasma-derived extracellular vesicles for regenerative medicine
Systematic-narrative review of platelet-rich plasma-derived extracellular vesicles and regenerative-medicine research.
Shedding light on the cell biology of extracellular vesicles
Fundamental review of extracellular-vesicle biology, biogenesis and intercellular communication.
Clinical Background
The research programs sit within broader reproductive-medicine evidence.
The protocols also draw on established literature concerning poor ovarian response, PCOS, chronic endometritis, adenomyosis, implantation failure and recurrent pregnancy loss.
A structured framework for describing low-prognosis patients undergoing ovarian stimulation.
Systematic-review literature addresses the relationship between chronic endometritis and altered embryo implantation.
Systematic review and meta-analysis have evaluated fertility, pregnancy and neonatal outcomes associated with adenomyosis.
Our Research
Building prospective evidence from current clinical pathways.
The current REGEN-AR studies are designed to document ovarian and endometrial outcomes prospectively in patients receiving Standard-PRP or IAS within routine clinical care.
ExoRegenOvo
Study 02-REGEN-AR · ovarian research at IVF Baden-Baden. Results are not yet presented as published study outcomes.
Study 02-REGEN-AR →RegenEndo
Study 03-REGEN-AR · endometrial research at IVF Baden-Baden. Results are not yet presented as published study outcomes.
Study 03-REGEN-AR →O-221
Regenerative endometrial PRGF treatment in patients with thin endometrium, recurrent implantation failure and recurrent miscarriages: a retrospective, self-controlled cohort study.
Human Reproduction ↗Scientific Interpretation
Evidence should clarify uncertainty, not hide it.
Current literature provides a scientific rationale for continued research, but important questions remain regarding patient selection, magnitude of effect and comparative clinical outcomes.
Published PRP studies cannot automatically be interpreted as clinical validation of IAS.
Biological evidence regarding growth factors or extracellular vesicles does not prove improved reproductive outcomes.
ExoRegenOvo and RegenEndo are prospective observational, non-randomized studies and must be interpreted accordingly.
Continue exploring
Evidence provides context. Research asks the next question.
Explore the scientific background, the ongoing REGEN-AR studies or the patient programs connected with ovarian and endometrial specialist evaluation.